Eli Lilly and Company’s tirzepatide led to superior weight reduction in people with obesity or overweight and type 2 diabetes, a trial evaluating the efficacy of the drug shows.
Detailed results from SURMOUNT-2 have revealed that 10 mg and 15 mg of tirzepatide met both co-primary endpoints and all key secondary endpoints compared to placebo for both estimands.
All six people treated with engrafted islet cells in a clinical trial produced endogenous insulin (C-peptide) and had improved glycaemic control while reducing or eliminating insulin use, according to results presented at the American Diabetes Association’s 83rd Scientific Sessions.
Vertex Pharmaceuticals Incorporated presented data on June 23 on all patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes with impaired hypoglycaemic awareness and severe hypoglycaemic events (SHEs).
Results from two studies evaluating the impact of mental health support for people with diabetes found significant benefits in patient outcomes.
As the number of diabetes cases continues to rise, addressing mental health challenges is a critical element in helping individuals with diabetes manage their care plan.
Diabetes distress for example includes the fears, worries, and burdens associated with the diabetes experience. Diabetes distress, which is distinct from depression, is common among adults with type 1 diabetes. To read more, click here.
Multi-disciplinary care between cardiologists, diabetes specialists and other team members can increase the prescriptions of evidence-based therapies to help treat people with both type 2 diabetes and heart disease, findings from the COORDINATE-Diabetes trial demonstrate.
The goal of this study was to evaluate if a coordinated, multi-faceted intervention of assessment, education, and feedback versus usual care of adults with type 2 diabetes would impact the prescription of three recommended evidence-based therapies, designed to help treat individuals with both diseases. To read more, click here.
An internationally recognised diabetes professor from Leicester has been presented with an honorary degree from the university he graduated from as a doctor in 1984.
The University of Dundee awarded the prestigious title to Professor Kamlesh Khunti CBE at this year’s summer graduation on Friday, June 23, for his profound and enduring contributions to improving the lives of people living with diabetes. To read more, click here.
A professor whose research is changing the management of diabetes in pregnancy has been recognised for her “outstanding contributions” with a top award from the American Diabetes Association (ADA).
Helen Murphy, Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia, was the recipient of the Norbert Freinkel Award as part of ADA’s 2023 Professional Membership Awards. To read more, click here.
Significant numbers of people are not receiving diagnosis codes despite having evidence of chronic kidney disease, according to research presented at the 16th International Primary Care Diabetes Europe Conference.
Researchers found that in the majority of cases, a sustained reduction of estimated glomerular filtration rate (eGFR) below 60 did not lead to a chronic kidney disease (CKD) diagnosis code on a patient’s health record. eGFR is one of two tests used in primary care to diagnose CKD and a result below 60 places a patient into stage 3 to 5, indicating that the patient is at high risk of an adverse event.
Investigative insulin icodec helped patients achieve significantly more time in target blood glucose range compared with once-daily basal insulin glargine, according to research presented at the American Diabetes Association’s 83rd Scientific Sessions.
The drug achieved primary endpoint by demonstrating superiority and non-inferiority in HbA1c reduction from baseline at week 52 in the data revealed on Sunday, June 25, from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin icodec.
The Department of Health and Social Care has announced there are “very limited, intermittent supplies” of all glucagon-like peptide-1 (GLP-1) receptor agonists.
The shortage has been caused by an increase in demand for these products for licensed and off-label indications, with the supply not expected to return to normal until at least mid-2024.
Healthcare professionals with an interest in diabetes can now access an online resource that outlines what language should be used when caring for those living with the condition.
This pocket-sized guide highlights how the language used in the care of those with diabetes has the power to promote positive stereotypes. To read more, click here.
Healthcare professionals with an interest in multidisciplinary diabetic foot care have been invited to an annual symposium being held by a leading foot clinic in September.
Registration is open for the 9th International Symposium on the Multidisciplinary Care and Surgical Reconstruction of the Diabetic Foot. To read more, click here.
Let me outline a journey for you in this blog, bear with me. The journey of getting access to technology for those living with type 1 diabetes as outlined through cards! A deck of cards holds four aces and over the last five to six years, here is how those aces have played out. To read more, click here.
Bringing you the latest jobs from around the country within the field of diabetes.
Diabetes Support Worker – East Sussex Healthcare NHS Trust
Diabetes Podiatry Technician – Cambridge University Hospital NHS Foundation Trust
Band 7 Diabetes Specialist Dietitian – University Hospitals Birmingham NHS Foundation Trust
Lead Pharmacist for Endocrinology & Diabetes – Warrington and Halton Teaching Hospitals NHSFT
Clinical Nurse Specialist – Diabetes – University Hospitals Birmingham NHS Foundation Trust
Join the expanding diabetes community on Twitter and follow us for the latest diabetes news updates at @DiabetesTimes.
We are now on YouTube where you will find interviews with leading figures within the field of diabetes. Click here to visit our page.
